AstraZeneca announced that its vaccine was 76% effective after updated clinical trial data

AstraZeneca’s covid-19 vaccine is 76% effective against symptomatic forms of the disease, the Anglo-Swedish laboratory announced on Wednesday in a press release., after updating data from a clinical trial conducted in the United States, Peru and Chile.

The results of the “primary analysis of phase III trials [de la vacuna] in the United States confirmed that (its) effectiveness was consistent “with the data announced on Monday, AstraZeneca said in its memo.

The laboratory also reported that its vaccine was 100% effective in preventing severe cases of covid-19, a figure similar to that previously announced.

AstraZeneca pledged Tuesday to provide recent figures within 48 hours to the US regulator overseeing these clinical trials, which had criticized potentially “outdated” data on its previously announced anti-covid vaccine, 79% effective in prevention cases.

This Tuesday, Anthony Fauci, The leading US epidemiologist said that the COVID-19 vaccine from AstraZeneca / Oxford it probably is “very good”, despite the fact that the data presented by the pharmaceutical company in a press release this week they were not “entirely correct”.

“It is probably a very good vaccine”, said Fauci, the president’s medical adviser for the pandemic Joe biden and director of National Institute of Allergies and Infectious Diseases (NIAID), al programa “Good Morning America” ​​of ABC News.

“If you look at it the data is pretty good, but when they put it out in the press release it wasn’t quite right.” Explain.

Fauci’s comments come after a security and data watchdog expressed “concern” that AstraZeneca may have included outdated data in its clinical trials in the United States which has been shown to be 79% effective against covid-19 and 100% in severe cases of the disease.

Fauci said that junta, a group of independent medical experts from National Institutes of Health, who understands NIAID, has contacted the company to express their concerns about the way the company presented the data What “they were somewhat overwhelmed and could actually be a bit misleading. “

The American expert described the event as “unlucky», And assured that it was “An unforced error” This only increases public doubts about vaccines and could potentially raise more questions.

Used by many countries, including the European Union, the vaccine developed by AstraZeneca and the University of Oxford has yet to be approved in the United States, where authorities have requested more data on trials of phase III carried out on their territory.

With information from AFP

KEEP READING: